Our clinical and scientific advisory board is comprised of professionals in the medical field who have experience treating, researching or teaching others about a neuroimmune disorder.
Please click on a picture to get more information.
Stewart Campbell, PhD
Senior Vice President, Research & Development – Axial Biotherapeutics, Inc.
Dr. Campbell has more than 26 years of research experience in drug discovery and development, including the past several years at Axial Biotherapeutics working to develop safe and effective therapies for improving the quality of life for children with autism. He has built and led research teams involved in a variety of environments from early stage research through to advanced clinical development in small start-ups to mid-sized companies. Through team work with capable colleagues he has been fortunate to have triaged several drug candidates from the idea stage to clinical proof-of-concept in multiple disease areas. He received a Ph.D. in Organic Chemistry from the Queen’s University (Canada), which was followed by post-doctoral research at Duke University. He has consulted for several start-up companies in multiple technology and therapeutic areas in the Greater Boston area and is co-inventor on more than 15 issued patents.
Stewart Campbell, PhD
Senior Vice President, Research & Development, Axial Biotherapeutics, Inc.
Wanjun Chen, MD
Senior Investigator and Chief of Mucosal Immunology
Dr. Chen is internationally recognized by his work focus on TGF-b regulation of immunity and tolerance. Dr. Chen discovered that TGF-b induces Foxp3 in CD4 T cells and converts them into regulatory T cells. He applies the mechanistic knowledge to animal models to understand the pathogenesis of autoimmunity and inflammation, cancer, and infectious disease. In particularly, he has developed an immunotherapy by inducing antigen-specific regulatory T cells for the treatment of experimental models of autoimmunity, including the EAE, an animal model of Multiple Sclerosis. His studies aim to lead to the development of potential immunotherapies for relevant human diseases.
Wanjun Chen, MD
Senior Investigator and Chief of Mucosal Immunology Section
Jennifer Frankovich, MD
Clinical Professor in the Department of Pediatrics, Division of Immunology & Rheumatology – Stanford University & Lucile Packard Children’s Hospital
Dr. Frankovich is a Clinical Professor in the Department of Pediatrics, Division of Allergy, Immunology Rheumatology (AIR) at Stanford University/Lucile Packard Children’s Hospital (LPCH). Her clinical expertise is in systemic inflammatory and autoimmune diseases that co-occur with psychiatric symptoms. She completed her training in pediatrics, pediatric rheumatology, and clinical epidemiology at Stanford University/LPCH. She directs the Stanford PANS Program (2012- present) where she and her collaborators have created a longitudinal clinical database and large biorepository of patient and control biospecimens. In addition to generating clinical data to better understand the PANS illness, she is collaborating with 10 basic science labs who aim to understand the immunological underpinnings of the illness.
Jennifer Frankovich, MD
Clinical Professor in the Department of Pediatrics, Division of Immunology & Rheumatology, Stanford University
Richard Frye, MD, PhD
Chief of the Division of Neurodevelopment Disorders – Phoenix Children’s Hospital
Dr. Richard Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He is the Chief of the Division of Neurodevelopmental Disorders at Phoenix Children’s Hospital and received an MD and PhD in Physiology and Biophysics from Georgetown University. He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children’s Hospital Boston and Fellowship in Psychology at Boston University. He also received a Masters in Biomedical Science and Biostatistics from Drexel University. He holds board certifications in General Pediatrics, and in Neurology with Special Competence in Child Neurology. He has authored over 150 peer-reviewed publications and book chapters, and serves on several editorial boards. He has conducted several clinical trials demonstrating the efficacy of safe and novel treatments that target underlying physiological abnormalities in children with neurodevelopmental disorders.
Richard Frye, MD, PhD
Chief of the Division of Neurodevelopment Disorders, Phoenix Children’s Hospital
Daniel Geller, MD
Founder of the Pediatric Obsessive-Compulsive Disorder Program, Pediatric OCD and Tic Disorder Program – Massachusetts General Hospital
Dr. Daniel Geller founded the Pediatric Obsessive-Compulsive Disorder (OCD) Program in 1992. For 25 years, he has studied the causes, phenomenology, developmental expression across the lifespan, psychiatric correlates, familial patterns, genetics, treatment and outcome of OCD and related disorders that onset in youth, including tic disorders, Tourette’s syndrome (TS) and ADHD and has produced a coherent and comprehensive body of original research. More than 150 publications include many original papers, reviews, book chapters, and new research presentations and symposia at national and international scientific meetings. At Massachusetts General Hospital (MGH), he has collected and characterized the largest sample of children and adolescents with OCD ever assembled.
Dr. Geller has won competitive grants from the National Institutes of Health (K08, R01), private foundations and industry. Dr. Geller is a founding member of the Psychiatric Genetics Consortium OCD/TS subgroup, collaborating with senior scientists from many different countries, with the goal of identifying genes responsible for OCD and delineating epigenetic mechanisms by which genetic vulnerabilities are translated into clinical symptoms. He authored the seminal research into pharmacological approaches to pediatric OCD and continues as a leading investigator of the effects of new molecules for OCD and TS and biomarkers for OCD. Most recently he has focused on inflammatory- and immune-mediated neuropsychiatric syndromes affecting children, as one cause of OCD in youth.
He is the author of the American Academy of Child and Adolescent Psychiatry practice guidelines for treatment of these children and is a Distinguished Fellow of the Academy. Dr. Geller is the recipient of many honors and awards in community medicine and developmental pediatrics, notably from the American Academy of Child and Adolescent Psychiatry, Obsessive-Compulsive Foundation, Tourette’s Syndrome Association and the Schwartz Center for Compassionate Care. He serves on expert national and international panels, including the National Institute for Clinical Excellence of the Royal College of Psychiatrists and the American Psychiatric Association. Dr. Geller is a Fellow of the American College of Neuropsychopharmacology, a board member of the International College of Obsessive Compulsive Spectrum disorders and is a Fellow of the Royal Australian College of Paediatrics.
Dr. Geller is an Associate Professor of Psychiatry at Harvard Medical School and has mentored a whole generation of young clinicians and psychiatry residents, many of whom have gone on to successful academic careers. In 2012, he was honored as the inaugural incumbent of the Mittelman Family Chair in Child and Adolescent Psychiatry at MGH and continues as Director of Research of the program he founded.
Daniel Geller, MD
Founder Pediatric OCD Program, Tic Disorder Program, Associate Professor of Psychiatry, Harvard Medical School
Brent T Harris, MD, PhD, FCAP
Associate Professor of Pathology and Neurology, Director of Neuropathology, Director – Georgetown Brain Bank at Georgetown University Hospital
Director, Histopathology and Tissue Shared Resource – MedStar Health/Georgetown University Medical Center
Dr. Harris is a tenured faculty member of Georgetown University with dual appointments in Neurology and Pathology. As a neuropathologist and physician-scientist Dr. Harris has clinical, research, and teaching interests in neurological and oncological diseases. He has active collaborations and research programs in his own lab in the areas of neurodegeneration and CNS neoplasia. His primary interest is in understanding how mechanisms of neuroinflammation and glial-neuronal communication influence the pathophysiology of neurological diseases. In addition to investigating disease processes he also seeks to uncover targets for pharmacological intervention.
Brent Harris, MD
Associate Professor of Pathology and Neurology, Director of Neuropathology, Director, Histopathology and Tissue Shared Resource – Georgetown Brain Bank at Georgetown University Hospital;
MedStar Health/Georgetown University
Harumi Jyonouchi, MD
Associate Professor, Division of Allergy, Immunology & Rheumatology – Rutgers University
Dr. Jyonouchi is a pediatric immunologist who has evaluated a substantial numbers of children with Autism Spectrum Disorder, focusing on allergic/immunological (A/I) conditions for years; first, at the University of Minnesota, then at Rutgers University-New Jersey Medical School (NJMS), and currently at Saint Peter’s University Hospital (SPUH), New Brunswick, NJ. Prior to becoming involved in research and clinical management of children with ASD, she trained as a clinical allergist/immunologist, as well as a physician scientist in the field of primary/secondary immunodeficiency, autoimmunity, and allergic disorders by the late Dr. Robert Good at Sloan-Kettering Institute for Cancer Research, Oklahoma Medical Research Foundation, All Children’s Hospital, and University of South Florida where she spent her early years, seeing patients diagnosed with primary immunodeficiency, allergic disorders, and secondary immunodeficiency caused by micronutrient deficiency.
Her work in these fields continued after relocating to the University of Minnesota (Pediatric Allergy/Immunology). Her first encounter with children with ASD was 18-19 years ago, when she had an opportunity of evaluating a child with food allergy (FA) and other underlying medical conditions. Evaluation of FA in children with ASD resulted in publications describing a high prevalence of non-IgE mediated FA (NFA). She has a long standing keen interest in the role that the immune system plays in children with ASD with NFA and other medical conditions. Later, her research focus shifted to a subset of children with ASD who have evidence of innate immune abnormalities as well as fluctuating behavioral symptoms and various co-morbid conditions. Through her years of research, she and her collaborators have accumulated evidence that intrinsic abnormalities of monocytes may be a common denominator that leads to variable clinical manifestation in a subset of children with ASD. In 2015, she transferred her research laboratory to SPUH along with the key personnel, Dr. Lee Geng, who has been instrumental in developing and conducting all the assays assessing monocyte functions and mRNA/miRNA purification. Dr. Jyonouchi has published over 100 papers.
Harumi Jyonouchi, MD
Associate Professor, Division of Allergy, Immunology & Rheumatology, Rutgers University
Ritika Kapoor, MB BS, MRCPCH, PhD
Consultant Paediatric Endocrinologist & Honorary Senior Lecturer – King’s College Hospital, NHS Foundation Trust, London
Dr. Ritika Kapoor is a Consultant in Paediatric Diabetes and Endocrinology and an Honorary Senior Lecturer at Kings College with a special interest in Hyperinsulinaemic Hypoglycaemia. She has been instrumental in setting up the Regional CAH clinic and has developed the Gynaecology-Endocrine service for adolescents at Kings.
Dr Kapoor obtained her primary medical degree from University of Mumbai in 1997. She then did her basic Paediatric training in London gaining the MRCPCH in 2001 and subsequently received her specialist Paediatric training on the East of England (Cambridge) Deanery. She trained in Paediatric Diabetes and Endocrinology at Addenbrooke’s Hospital, Cambridge and the Great Ormond Street Hospital in London. Following this she did her formal research on Genetics of Congenital Hyperinsulinism with Prof. Khalid Hussain at Institute of Child Health & Great Ormond Street Hospital, London and obtained her PhD from University College London in 2010.
Complementing her clinical practice, her research interests centre around disorders of glucose metabolism and is considered as one of the opinion leaders in the field of Hyperinsulinism. She has authored a number of publications (Google Scholar) and book chapters and lectures regularly at national and international meetings.
Ritika Kapoor, MB, BS, MRCPCH, PhD
Consultant Paediatric Endocrinologist & Honorary Senior Lecturer, King’s College Hospital NHS Foundation Trust
Vikas Khanduja, MB BS, MA, MRCS, MSc, FRCS
Consultant Orthopaedic Surgeon & Lead for Elective Clinical Trials – Cambridge University Hospital NHS Trust
Dr. Vikas Khanduja is a Consultant Orthopaedic Surgeon specializing in hip and knee surgery and has a particular interest in arthroscopic surgery of the hip. He has been instrumental in setting up & developing the tertiary referral service for Young Adult Hip Surgery in Cambridge. Complementing his clinical practice, his research interests centre around disease stratification of FAI using novel imaging techniques, better pre-operative planning tools using dynamic analysis and optimization of arthroscopic management of FAI via precision surgery to improve outcomes. He has authored over 100 peer reviewed articles (Pubmed) and three books. He is the recipient of the American and British Hip Society Traveling Fellowship in 2011, the Arnott Medal presented by the Royal College of Surgeons of England in 2013 and the Insall Fellowship presented by the American Knee Society and Insall Foundation in 2014. Dr. Khanduja sits on the Board of Directors for SICOT as Chair of Education Academy, the British Hip Society as the Vice President, ESSKA as the Chair of the Hip Arthroscopy Committee and the NIHR MSK NSG as the Orthopaedic Lead for the Eastern Region. He is also the Associate Editor to the Bone and Joint Journal & the past chair to the Non Arthroplasty Hip Registry (NAHR).
Vikas Khanduja MB BS, MA, MRCS, MSc, FRCS
Consultant Orthopaedic Surgeon & Lead for Elective Clinical Trials, Addenbrooke’s – Cambridge University Hospital NHS Trust
John Lukens, PhD
Associate Professor of Neuroscience, Center for Brain Immunology and Glia (BIG) – University of Virginia
John Lukens, PhD is an associate professor at the University of Virginia and runs the Luken lab in the Department of Neuroscience and the Center for Brain Immunology and Glia. His lab investigates roles for IL-1 family cytokines and caspase-mediated signaling in the pathogenesis of multiple sclerosis, traumatic brain injury, neurodegenerative disease and autism spectrum disorder. They are particularly interested in discovering novel inflammatory pathways that contribute to maternal immune activation-induced autism and interrogating the efficacy of immune-based approaches in the treatment of autism.
He and his lab are actively investigating the cellular and molecular pathways that contribute to neuroinflammation and central nervous system (CNS)-related tissue damage. And particularly interested in elucidating the mechanisms that regulate inflammatory cytokine production in the CNS in response to both tissue injury and CNS infection. To this end, they utilize models of multiple sclerosis, CNS injury, neurodegenerative disease, autism spectrum disorder and CNS infection to identify the cell types and molecular pathways that are responsible for neuroinflammation. Future work in his lab will focus on further characterizing the immunological signaling pathways that control neuroinflammation in models of neurodegeneration, CNS injury and CNS infection.
Luken also explores how modulation of the microbial landscape in the intestine influences the development of CNS disorders. Emerging data suggests that crosstalk between the intestinal microbiome (collection of trillions of microbes that peacefully live within us) and the brain is a pivotal regulator of many CNS diseases; however , the mechanisms by which the microbiome can influence CNS disease pathogenesis remain poorly defined. Luken’s work is aimed at investigating how microbiota-dependent control of immune responses specifically influences neurological disease pathogenesis, CNS function and mental health.
John Luken, PhD
Associate Professor of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia
Naveen Nagarajan, PhD
Postdoctoral Associate, Dr. Mario Capecchi Lab, Eccles Institute of Human Genetics – University of Utah
Naveen Nagarajan is Postdoctoral associate in the laboratory of Dr. Mario Capecchi at the Department of Human Genetics, University of Utah. His work is focused on investigating the neural circuit and cellular mechanisms underlying microglia-neuronal interaction in repetitive behaviors using multidisciplinary neuroscience approaches that include genetics, behavioral, optogenetics, miniature fluorescence endoscopy, electrophysiological and computational approaches. Dr. Nagarajan received his PhD in Chemistry with specialization in Biophysics and Neuroscience from the Department of Membrane Biophysics, Max Planck Institute for Biophysical chemistry, Goettingen, Germany under the able guidance of Dr. Christian Rosenmund and Dr. Erwin Neher. He did a postdoctoral fellowship in cellular neuroscience in Mark Bear’s lab at the Picower Institute for Learning and Memory at MIT and systems neuroscience at the Keck Center for Integrative Neuroscience at the University of California, San Francisco with Dr. Michael Merzenich. He joined Dr. Mario Capecchi’s laboratory as a Postdoctoral fellow in 2009 to investigate the role of Hoxb8 gene function in repetitive, anxiety and social behavioral functions in Hoxb8 mutant mouse model of repetitive behaviors. Combining functional magnetic resonance imaging and whole brain imaging techniques in conjunction with electron microscopy and electrophysiological approaches, Dr. Nagarajan discovered corticostriatal circuit defect in Hoxb8 mutants. Unlike mutations in other neuronal genes that lead to repetitive behaviors, Hoxb8 gene is exclusively expressed in 30% of the brain microglia. Using optogenetics and miniature endofluorescence imaging techniques the team for the first time discovered that the optogenetic stimulation of Hoxb8 microglia could induce repetitive grooming behavior in a control mouse. This resulted in a paradigm shift on how brain utilizes unique microglial function and capabilities to generate specific behaviors in circuit dependent and cell specific fashion. These studies provide a novel research direction and insights to unravel the mechanisms of microglia-neuronal communication in repetitive behaviors. The communicative signals between the brain’s immune cell and neural circuit is the first of its kind that will lead to the elucidation of how mutations in immune cell, the response of the neural circuit and the brain microenvironment directly impacts the cognitive, emotional and social function of brain in healthy and disease states.
Naveen Nagarajan, PhD
Postdoctoral Associate, Dr. Mario Capecchi Lab, Eccles Institute of Human Genetics, University of Utah
Chris Pittenger, MD, PhD
Professor of Psychiatry
Yale University
Chris Pittenger earned his MD and Ph.D. degrees from Columbia University, where his graduate work was done with Nobel Prize recipient Eric Kandel. He returned to Yale University, his undergraduate alma mater, for residency and research training in psychiatry in 2003. He joined the faculty as an Assistant Professor in 2007 and is now a tenured Associate Professor and Assistant Chair for Translational Research in the Department of Psychiatry .
During his Ph.D. studies in basic neurobiology, he became fascinated by the brain’s ability to go on autopilot — to perform complex series of actions or thoughts, after sufficient rehearsal, with almost no conscious effort. Then, during his clinical training, he recognized how this process, when disrupted by disease, can lead to the maladaptive and disruptive automaticity seen in many neuropsychiatric disorders. His research, both with patients and in animal models, aims to elucidate the mechanisms of learned automatic behaviors and to better understand the consequences when they go awry, with the ultimate goal of developing new understandings and better treatments for a variety of neuropsychiatric conditions.
Dr. Pittenger’s research and clinical work have been acknowledged by a number of prestigious awards, including grant funding from the National Institute of Mental Health, the National Institute of Neurological Disease and Stroke, NARSAD, the Tourette Syndrome of America, the Doris Duke Charitable Trust, and other organizations. He has won a number of honorific awards, including from the National Institute of Mental Health, the Society for Neuroscience, the American College of Neuropsychopharmacology, the American Psychiatric Association, and the American College of Psychiatrists. He is a member of the Scientific Advisory Board of the International OCD Foundation and Chair of both their Grant Review Committee and their Annual Research Symposium Planning Committee. He is a Fellow of the American College of Neuropsychopharmacology, the American Psychiatric Association, and the American Neurological Association.
Chris Pittenger, MD, PhD
Professor of Psychiatry; Assistant Chair for Translational Research, Psychiatry; Director, Yale OCD Research Clinic; Director, Neuroscience Research Training Program, Yale Department of Psychiatry
Erin E. Masterson, PhD, MPH
Environmental & Occupational Health Sciences, School of Public Health – University of Washington
Erin E. Masterson, PhD, MPH is an Epidemiologist at the University of Washington in Seattle. She has partnered with the Pediatric Research & Advocacy Initiative (PRAI) since 2018 to develop and launch the International PANS Registry (IPR). Today she continues to work alongside PRAI to manage and analyze the IPR data. In general, Erin’s research focuses on the developmental origins and social determinants of health. Specifically, she is working on developing methods that will allow teeth (through developmental defects in the enamel) to be used as biomarkers of early life exposures and a potential clinical screening tool for predicting health risk throughout the life course.
Erin Masterson, PhD, MPH
Epidemiologist, School of Public Health, University of Washington, Seattle
Sarkis K. Mazmanian, PhD
Professor of Microbiology, Division of Biology & Biological Engineering – California Institute of Technology
Sarkis K Mazmanian, PhD, is the Luis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology (Caltech). He is a Phi Beta Kappa graduate from the University of California, Los Angeles, where Dr. Mazmanian also received his doctoral training in microbiology and immunology studying the mechanism by which Gram-positive pathogens anchor surface protein adhesins during bacterial infection. He was a Helen Hay Whitney Post-doctoral Fellow at Harvard Medical School where he studied how symbiotic bacteria promote healthy maturation of the immune system. He was promoted to assistant professor at Harvard Medical School in 2006, and later that year moved to Caltech to start his independent laboratory. Dr. Mazmanian has won numerous awards including a Searle Scholar, Young Investigator of the Year at Harvard Medical School, Damon Runyon Innovation Award, was named by Discover Magazine as one of the “Best Brains in Science under 40” and recently received the MacArthur Foundation “Genius” award. His laboratory currently focuses on the study of beneficial bacterial molecules from the human gut microbiome as novel therapies for immunologic and neurologic disorders. This research has led to identification of novel drug candidates being developed for Inflammatory Bowel Disease, Autism Spectrum Disorder, and Parkinson’s disease. He is a founder of 2 biotech companies and serves on the Scientific Advisory Board of over a dozen companies, academic centers and not-for-profit foundations. Most importantly, Dr. Mazmanian has trained numerous students and fellows who have gone on to successful independent careers in academia, industry, and medicine.
Sarkis Mazmanian, PhD
Professor of Microbiology, Division of Biology & Biological Engineering, California Institute of Technology
Sam Pleasure, MD, PhD
Glenn W. Johnson, Jr. Memorial Endowed Chair in Neurology – University of California, San Francisco
Dr. Sam Pleasure is the Glenn W. Johnson, Jr. Memorial Endowed Chair in Neurology at UCSF. Dr. Pleasure is a neurologist who specializes in caring for patients with multiple sclerosis. He also has expertise in caring for patients with epilepsy as well as years of experience in managing a variety of neurological conditions in both clinic and hospital settings. Dr. Pleasure has two main areas of inquiry for his research. He studies processes that regulate early brain development in both normal and diseased situations. He also studies autoimmune forms of meningoencephalitis, where inflammation in specific brain areas causes severe neurologic dysfunction. Pleasure received his medical degree and a doctorate in neuroscience from the University of Pennsylvania. He was chief resident during his neurology residency at UCSF, where he then completed a research fellowship in neuroscience Pleasure is a fellow of the American Neurological Association and a member of the American Academy of Neurology, American Epilepsy Society, Society for Neuroscience, Society for Developmental Biology and Cajal Club. He has won numerous awards for his research and has received research funding from a wide variety of private, state and federal sources. He has served in leadership roles in national organizations and in the UCSF Department of Neurology.
Sam Pleasure, MD, PhD
Glenn W. Johnson, Jr. Memorial Endowed Chair in Neurology, University of California, San Francisco
Emily Severance, PhD
Assistant Professor of Pediatrics – Johns Hopkins University School of Medicine
Dr. Emily G. Severance is an assistant professor of pediatrics at the Johns Hopkins University School of Medicine. She is a member of the Stanley Division of Developmental Neurovirology research team and has served with the Scott-Gentle Foundation of The Brain and Behavior Research Foundation and the Johns Hopkins Silvio O. Conte Center for SchizophreniaResearch. As part of her ongoing research program, Dr. Severance focuses on the major gateway of the immune system, the gastrointestinal mucosa, where inflammation, food hypersensitivities, barrier defects and immune dysregulation can cause downstream brain dysfunction in people with psychiatric disorders. She is also involved in research studies of
COVID-19 and the roles of other viral, bacterial and fungal pathogens in mental illness. Dr. Severance earned her B.S. from the University of Maryland and her Ph.D. from the University of South Florida.
Emily Severance, PhD
Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine
Robert Yolken, MD
Professor of Neurovirology in Pediatrics – Johns Hopkins University School of Medicine
Dr. Robert H. Yolken is the Theodore and Vada Stanley Distinguished Professor of Neurovirology in the Department of Pediatrics at the Johns Hopkins University School of Medicine. He is also the chair of the Stanley Division of Pediatric Neurovirology, the nation’s first pediatric research center designed to investigate links between severe mental illness (including schizophrenia and manicdepressive disorders) and early childhood viral infection.
He and his research colleagues speculate that infectious agents can invade the brain and then lie dormant for years before triggering the onset of schizophrenia or manic-depressive illness in adolescence and young adulthood. Neuropathogenic microorganisms can also affect cognition and behavior through alterations in the immune system of the microbiome. They are investigating as possible microbial triggers Herpesviruses, Influenza viruses, and Coronaviruses, as well as Toxoplasma gondii which is a protozoan which can be transmitted to humans by cats and undercooked meat from farm animals. They believe that in the future antiviral, antimicrobial, or anti-inflammatory medications might be developed to treat or prevent schizophrenia in some individuals.
The overall goal of the research laboratory is to develop a training and research program devoted to the elucidation of the role of infection and immunity in the etiology of schizophrenia and bipolar disorders as well as suicide behaviors. Interests also include elucidating the role of perinatal infections in subsequent brain development.
Dr. Yolken received his M.D. from Harvard Medical School and completed a residency at Yale New Haven Hospital. He also trained at the National Institutes of Health before joining the Hopkins faculty in 1979.
He is author or coauthor of more than 500 scientific papers as well as Beasts of the Earth and several editions of the Manual of Clinical Microbiology.
Robert Yolken, MD
Professor of Neurovirology in Pediatrics, Johns Hopkins University School of Medicine, School of Public Health
